TARGETED PROFILING OF CRITICALLY ILL SARS-CoV-2 SUBJECTS: FROM TRANSCRIPTOME TO PROTEOME

Date:  November 9th, 2020

Time: 10:00am PDT

SARS-CoV-2 continues to spread rapidly with critically ill patients admitted to the intensive care unit (ICU), where the mortality rate is reported to be 31-40%. This webinar will present multiple SARS-CoV-2 investigations to elucidate pathophysiology of subjects suspected of being infected with SARS-CoV-2 and admitted to the ICU using standardized hospital screening methodologies. Specifically, blood samples were collected until either testing was confirmed SARS-CoV-2 negative on ICU day 3, or until ICU discharge/death if the subject tested SARS-CoV-2 positive. Blood samples were profiled using multiple state-of-the-art technologies. Our data suggest that SARS-CoV-2 infection causes an excessive release of inflammatory mediators, including TNF and serine proteases, together with microvascular thrombi formation secondary to endothelial injury/activation and glycocalyx degradation. Targeted metabolomics identified SARS-CoV-2 metabolite changes that may be useful diagnostically, while targeted proteomics identified novel SARS-CoV-2 outcome prognostic biomarkers. Finally, critically ill SARS-CoV-2 subjects demonstrate robust serological responses dominated by significant elevations in selective SARS-CoV-2 IgG. Taken together, our data demonstrate that SARS-CoV-2 initiates a unique immune response with our recent studies elucidating key pathophysiological mechanisms.

Learning Objectives:

• Provide new insight on the SARS-CoV-2 Immune Response
• Introduce Novel SARS-CoV-2 Diagnostic and Prognostic Biomarkers
• Value of ProcartaPlex Human Coronavirus Ig total 11-plex Panel

Webinars will be available for unlimited on-demand viewing after live event.

LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.